- Home
- IRWD vs SVRA Comparison
IRWD vs SVRA Comparison
Compare IRWD & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRWD
- SVRA
- Stock Information
- Founded
- IRWD 1998
- SVRA N/A
- Country
- IRWD United States
- SVRA United States
- Employees
- IRWD N/A
- SVRA N/A
- Industry
- IRWD Biotechnology: Pharmaceutical Preparations
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- IRWD Health Care
- SVRA Health Care
- Exchange
- IRWD Nasdaq
- SVRA Nasdaq
- Market Cap
- IRWD 510.5M
- SVRA 590.4M
- IPO Year
- IRWD 2010
- SVRA N/A
- Fundamental
- Price
- IRWD $3.53
- SVRA $3.22
- Analyst Decision
- IRWD Buy
- SVRA Buy
- Analyst Count
- IRWD 4
- SVRA 6
- Target Price
- IRWD $12.00
- SVRA $10.17
- AVG Volume (30 Days)
- IRWD 1.9M
- SVRA 1.7M
- Earning Date
- IRWD 02-13-2025
- SVRA 11-12-2024
- Dividend Yield
- IRWD N/A
- SVRA N/A
- EPS Growth
- IRWD N/A
- SVRA N/A
- EPS
- IRWD N/A
- SVRA N/A
- Revenue
- IRWD $378,418,000.00
- SVRA N/A
- Revenue This Year
- IRWD N/A
- SVRA N/A
- Revenue Next Year
- IRWD N/A
- SVRA N/A
- P/E Ratio
- IRWD N/A
- SVRA N/A
- Revenue Growth
- IRWD N/A
- SVRA N/A
- 52 Week Low
- IRWD $3.06
- SVRA $2.82
- 52 Week High
- IRWD $15.70
- SVRA $5.70
- Technical
- Relative Strength Index (RSI)
- IRWD 44.66
- SVRA 42.99
- Support Level
- IRWD $3.39
- SVRA $3.35
- Resistance Level
- IRWD $4.05
- SVRA $3.40
- Average True Range (ATR)
- IRWD 0.30
- SVRA 0.22
- MACD
- IRWD 0.02
- SVRA -0.01
- Stochastic Oscillator
- IRWD 47.47
- SVRA 6.20
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.